Researchers at the University of California, Irvine have developed a 3D human colon model integrated with bioelectronics to ...

Aranscia® solutions help oncologists comply with new FDA warning label requiring  DPYD genetic testing in patients receiving select chemotherapies ...

Received folinic acid/fluorouracil/oxaliplatin/bevacizumab in first line with initial partial response; progression after 11 ...

Researchers at the University of California, Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery.

The plan-act-study-do QI methodology was used to identify potential hazardous drug exposures and implement procedures to minimize those risks.

Apnimed Inc., a pharmaceutical company developing first-in-class oral drugs that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced ...

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical and preclinical ...

A paper last month in the Journal of Clinical Oncology reported on the pooled analysis of data showing that the use of neoadjuvant immune checkpoint inhibitors work better than the frequently used ...

Dr Anjali Pathak discusses four cases of skin cancer or pre-cancer - involving potentially malignant skin lesions - and their management ...

REGIONS NEWS NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress ...

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows ...